L3VLUP
ProSign in

PCRX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PCRXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PCRX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPCRXVRTX
Q3 20205 holders, $344m31 holders, $21.9bn
Q4 20205 holders, $335m30 holders, $18.4bn
Q1 20214 holders, $313m31 holders, $15.4bn
Q2 20216 holders, $303m30 holders, $12.7bn
Q3 20216 holders, $251m35 holders, $10.1bn
Q4 20216 holders, $269m28 holders, $12.4bn
Q1 20226 holders, $332m23 holders, $16.1bn
Q2 20225 holders, $239m25 holders, $18.1bn
Q3 20225 holders, $206m22 holders, $18.4bn
Q4 20225 holders, $144m28 holders, $18.4bn
Q1 20236 holders, $174m26 holders, $21.4bn
Q2 20238 holders, $174m27 holders, $24.7bn
Q3 20235 holders, $111m33 holders, $24.3bn
Q4 20235 holders, $102m32 holders, $28.6bn
Q1 20243 holders, $108m31 holders, $29.8bn
Q2 20244 holders, $113m29 holders, $33.4bn
Q3 20244 holders, $41m27 holders, $33.5bn
Q4 20244 holders, $68m26 holders, $28.5bn
Q1 20257 holders, $178m21 holders, $35.4bn
Q2 20255 holders, $117m21 holders, $32.3bn
Q3 20254 holders, $109m22 holders, $25.9bn
Q4 20255 holders, $57m26 holders, $31.8bn
Q1 20263 holders, $45m25 holders, $31.8bn
Q2 20263 holders, $49m26 holders, $34.6bn
PCRX

Pacira Biosciences Inc

Holders
3
Reported value
$45m
Buyers
6
Sellers
20

Breadth -14 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PCRX (1)

PDT Partners LLC

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →